DNA damage response specialist Artios Ltd. raised $115 million in an oversubscribed Series D round to advance its first‑in‑class DDR programs after delivering encouraging Phase 1/IIa data for its lead candidates. The financing is intended to support mid‑stage trials and biomarker development across multiple oncology indications. Artios has focused on exploiting synthetic lethality and tumor DNA repair vulnerabilities, positioning its assets as combination partners with standard-of-care therapies and immunotherapies. Company executives indicated the funds will accelerate patient‑selection strategies and expand clinical sites for ongoing studies. The round underscores sustained venture and crossover investor interest in DDR biology as a route to differentiated cancer medicines and potential combination strategies that can broaden patient populations.